Advanced

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Fjordén, Karin LU ; Linderoth, Johan LU ; Nyman, Heidi; Ehinger, Mats LU ; Joost, Patrick; Bendahl, Pär-Ola LU ; Leppä, Sirpa and Jerkeman, Mats LU (2010) In Leukemia & lymphoma 51. p.1643-1648
Abstract
We have previously shown that expression of CD40 has a favorable prognostic impact in diffuse large B-cell lymphoma (DLBCL) after anthracycline-based chemotherapy. Here we examined the prognostic value of immunohistochemically defined CD40 expression in 95 patients with DLBCL treated with both anthracycline-based chemotherapy and rituximab. Using a 10% cut-off level, 77% of the patients had CD40-positive tumors and showed a superior overall survival (p = 0.02 log-rank, hazard ratio 0.35, 95% CI 0.14-0.88, p = 0.03 Cox regression). When adjusted for International Prognostic Index in multivariate analysis, CD40 was not an independent prognostic factor (hazard ratio 0.39, 95% CI 0.15-1.04, p = 0.06 Cox regression). However, even after the... (More)
We have previously shown that expression of CD40 has a favorable prognostic impact in diffuse large B-cell lymphoma (DLBCL) after anthracycline-based chemotherapy. Here we examined the prognostic value of immunohistochemically defined CD40 expression in 95 patients with DLBCL treated with both anthracycline-based chemotherapy and rituximab. Using a 10% cut-off level, 77% of the patients had CD40-positive tumors and showed a superior overall survival (p = 0.02 log-rank, hazard ratio 0.35, 95% CI 0.14-0.88, p = 0.03 Cox regression). When adjusted for International Prognostic Index in multivariate analysis, CD40 was not an independent prognostic factor (hazard ratio 0.39, 95% CI 0.15-1.04, p = 0.06 Cox regression). However, even after the introduction of immunochemotherapy, CD40 has a potential prognostic impact in DLBCL. Additional and larger studies are necessary, regarding the immunohistochemical robustness of CD40 and the biological mechanisms that contribute to the superior prognosis in CD40-expressing DLBCL. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia & lymphoma
volume
51
pages
1643 - 1648
publisher
Taylor & Francis
external identifiers
  • WOS:000282233200010
  • PMID:20593977
  • Scopus:77956324601
ISSN
1029-2403
DOI
10.3109/10428194.2010.492537
language
English
LU publication?
yes
id
6a36ce2e-5d6e-4298-b459-f5eb0ce888f8 (old id 1645362)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20593977?dopt=Abstract
date added to LUP
2010-08-02 09:51:03
date last changed
2016-10-14 12:44:28
@misc{6a36ce2e-5d6e-4298-b459-f5eb0ce888f8,
  abstract     = {We have previously shown that expression of CD40 has a favorable prognostic impact in diffuse large B-cell lymphoma (DLBCL) after anthracycline-based chemotherapy. Here we examined the prognostic value of immunohistochemically defined CD40 expression in 95 patients with DLBCL treated with both anthracycline-based chemotherapy and rituximab. Using a 10% cut-off level, 77% of the patients had CD40-positive tumors and showed a superior overall survival (p = 0.02 log-rank, hazard ratio 0.35, 95% CI 0.14-0.88, p = 0.03 Cox regression). When adjusted for International Prognostic Index in multivariate analysis, CD40 was not an independent prognostic factor (hazard ratio 0.39, 95% CI 0.15-1.04, p = 0.06 Cox regression). However, even after the introduction of immunochemotherapy, CD40 has a potential prognostic impact in DLBCL. Additional and larger studies are necessary, regarding the immunohistochemical robustness of CD40 and the biological mechanisms that contribute to the superior prognosis in CD40-expressing DLBCL.},
  author       = {Fjordén, Karin and Linderoth, Johan and Nyman, Heidi and Ehinger, Mats and Joost, Patrick and Bendahl, Pär-Ola and Leppä, Sirpa and Jerkeman, Mats},
  issn         = {1029-2403},
  language     = {eng},
  pages        = {1643--1648},
  publisher    = {ARRAY(0xa3caaa0)},
  series       = {Leukemia & lymphoma},
  title        = {CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.},
  url          = {http://dx.doi.org/10.3109/10428194.2010.492537},
  volume       = {51},
  year         = {2010},
}